BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 19922329)

  • 1. Serum levels of NT-proBNP as surrogate for cardiac amyloid burden: new evidence from gadolinium-enhanced cardiac magnetic resonance imaging in patients with amyloidosis.
    Lehrke S; Steen H; Kristen AV; Merten C; Lossnitzer D; Dengler TJ; Katus HA; Giannitsis E
    Amyloid; 2009 Dec; 16(4):187-95. PubMed ID: 19922329
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis.
    Palladini G; Campana C; Klersy C; Balduini A; Vadacca G; Perfetti V; Perlini S; Obici L; Ascari E; d'Eril GM; Moratti R; Merlini G
    Circulation; 2003 May; 107(19):2440-5. PubMed ID: 12719281
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognosis assessment of cardiac involvement in systemic AL amyloidosis by magnetic resonance imaging.
    Mekinian A; Lions C; Leleu X; Duhamel A; Lamblin N; Coiteux V; De Groote P; Hatron PY; Facon T; Beregi JP; Hachulla E; Launay D;
    Am J Med; 2010 Sep; 123(9):864-8. PubMed ID: 20800158
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular magnetic resonance and prognosis in cardiac amyloidosis.
    Maceira AM; Prasad SK; Hawkins PN; Roughton M; Pennell DJ
    J Cardiovasc Magn Reson; 2008 Nov; 10(1):54. PubMed ID: 19032744
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Best use of cardiac biomarkers in patients with AL amyloidosis and renal failure.
    Palladini G; Foli A; Milani P; Russo P; Albertini R; Lavatelli F; Obici L; Perlini S; Moratti R; Merlini G
    Am J Hematol; 2012 May; 87(5):465-71. PubMed ID: 22389105
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis.
    Dispenzieri A; Gertz MA; Kyle RA; Lacy MQ; Burritt MF; Therneau TM; Greipp PR; Witzig TE; Lust JA; Rajkumar SV; Fonseca R; Zeldenrust SR; McGregor CG; Jaffe AS
    J Clin Oncol; 2004 Sep; 22(18):3751-7. PubMed ID: 15365071
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The interrelationship between preoperative anemia and N-terminal pro-B-type natriuretic peptide: the effect on predicting postoperative cardiac outcome in vascular surgery patients.
    Goei D; Flu WJ; Hoeks SE; Galal W; Dunkelgrun M; Boersma E; Kuijper R; van Kuijk JP; Winkel TA; Schouten O; Bax JJ; Poldermans D
    Anesth Analg; 2009 Nov; 109(5):1403-8. PubMed ID: 19843778
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Variables associated with contrast-enhanced cardiovascular magnetic resonance in hypertrophic cardiomyopathy: clinical implications.
    Payá E; Marín F; González J; Gimeno JR; Feliu E; Romero A; Ruiz-Espejo F; Roldán V; Climent V; de la Morena G; Valdés M
    J Card Fail; 2008 Jun; 14(5):414-9. PubMed ID: 18514934
    [TBL] [Abstract][Full Text] [Related]  

  • 9. N-terminal pro-brain natriuretic peptide, kidney disease and outcome in patients with chronic heart failure.
    Bruch C; Reinecke H; Stypmann J; Rothenburger M; Schmid C; Breithardt G; Wichter T; Gradaus R
    J Heart Lung Transplant; 2006 Sep; 25(9):1135-41. PubMed ID: 16962477
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NT-proBNP levels in the evaluation of right ventricular dysfunction in patients with coronary artery disease and abnormal left ventricular wall motion: a magnetic resonance imaging study.
    Krittayaphong R; Boonyasirinant T; Saiviroonporn P; Udompunturak S
    Coron Artery Dis; 2008 Nov; 19(7):481-7. PubMed ID: 18923244
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hyperthyroidism may affect serum N-terminal pro-B-type natriuretic peptide levels independently of cardiac dysfunction.
    Arikan S; Tuzcu A; Gokalp D; Bahceci M; Danis R
    Clin Endocrinol (Oxf); 2007 Aug; 67(2):202-7. PubMed ID: 17547691
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gadolinium-enhanced cardiovascular magnetic resonance and exercise capacity in hypertrophic cardiomyopathy.
    Romero-Puche A; Marín F; González-Carrillo J; García-Honrubia A; Climent V; Feliu E; Ruiz-Espejo F; Payá E; Gimeno-Blanes JR; de la Morena G; Valdés-Chavarri M
    Rev Esp Cardiol; 2008 Aug; 61(8):853-60. PubMed ID: 18684368
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incremental value of high-sensitivity C-reactive protein and N-terminal pro-B-type natriuretic peptide for the prediction of postoperative cardiac events in noncardiac vascular surgery patients.
    Goei D; Hoeks SE; Boersma E; Winkel TA; Dunkelgrun M; Flu WJ; Schouten O; Bax JJ; Poldermans D
    Coron Artery Dis; 2009 May; 20(3):219-24. PubMed ID: 19322079
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Usefulness of NT-proBNP level for diagnosing left ventricular hypertrophy in hypertensive patients. A cardiac magnetic resonance study.
    Morillas P; Castillo J; Quiles J; Nuñez D; Guillén S; Maceira A; Rivera M; Bertomeu V
    Rev Esp Cardiol; 2008 Sep; 61(9):972-5. PubMed ID: 18775240
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Plasma levels of N-terminal pro-brain natriuretic peptide and glycogen phosphorylase isoenzyme BB in neonates with asphyxia complicated by myocardial injury].
    Lin LX; Mao QH; Zhang ZL; An CX; Kang XG
    Zhongguo Dang Dai Er Ke Za Zhi; 2010 Apr; 12(4):252-5. PubMed ID: 20416213
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elevated plasma N-terminal pro-brain natriuretic peptide levels in acute ischemic stroke.
    Iltumur K; Yavavli A; Apak I; Ariturk Z; Toprak N
    Am Heart J; 2006 May; 151(5):1115-22. PubMed ID: 16644347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extracellular volume quantification by dynamic equilibrium cardiac computed tomography in cardiac amyloidosis.
    Treibel TA; Bandula S; Fontana M; White SK; Gilbertson JA; Herrey AS; Gillmore JD; Punwani S; Hawkins PN; Taylor SA; Moon JC
    J Cardiovasc Comput Tomogr; 2015; 9(6):585-92. PubMed ID: 26209459
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Abnormal gadolinium kinetics in cardio MRI - always an indication of cardiac amyloidosis?].
    Baeßler B; Reuter H; Huntgeburth M; Bunck AC
    Rofo; 2015 Mar; 187(3):189-91. PubMed ID: 25184217
    [No Abstract]   [Full Text] [Related]  

  • 19. Risk stratification for patients undergoing nonurgent percutaneous coronary intervention using N-terminal pro-B-type natriuretic peptide: a Clopidogrel for the Reduction of Events During Observation (CREDO) substudy.
    Tang WH; Steinhubl SR; Van Lente F; Brennan D; McErlean E; Maroo A; Francis GS; Topol EJ
    Am Heart J; 2007 Jan; 153(1):36-41. PubMed ID: 17174634
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of usefulness of N-terminal pro-brain natriuretic peptide as an independent predictor of cardiac function among admission cardiac serum biomarkers in patients with anterior wall versus nonanterior wall ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
    Haeck JD; Verouden NJ; Kuijt WJ; Koch KT; Van Straalen JP; Fischer J; Groenink M; Bilodeau L; Tijssen JG; Krucoff MW; De Winter RJ
    Am J Cardiol; 2010 Apr; 105(8):1065-9. PubMed ID: 20381654
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.